UBS Global Biopharma Conference - CARDIFF ONCOLOGY INC
Explicit Guidance:
- Runway: Cash balance of approximately $34 million (as of Q3) is sufficient to fund operations through Q3 2027.
- Trial Initiation: Targeting the first quarter of 2027 for the staged initiation of the Phase 3 registrational trial.
Business-Segment Outlook:
- Metastatic Colorectal Cancer (mCRC): Aiming to change the treatment paradigm for RAS-mutated mCRC in the first-line setting; current standard of care has seen no innovation in over 20 years.
- Chronic Myelomonocytic Leukemia (CMML): Observing promising monotherapy signals in a relapsed/refractory setting (OS ~6–8 months historically); expecting updated data presentation at the American Society of Hematology (ASH) meeting in December; currently investigating monotherapy activity.
- Small Cell Lung Cancer (SCLC): Early signals of monotherapy activity observed; has received Orphan Drug Designation.
- Product Selection: Advancing Onvancitib 30mg combined with Folfiri-Bev as the definitive dose and regimen for Phase 3 based on superior response rates (~70% ORR) and depth of response compared to FOLFOX-Bev combinations.
Market and Competitive Outlook:
- Addressable Population: Targeting ~50% of metastatic colorectal cancer patients who harbor RAS mutations (PAN-RAS); competitors focus on MSS populations, G12C inhibitors (small fraction), or PD-1/VEGF inhibitors not specifically targeting RAS mutations.
- Differentiation: Unique mechanism addressing RAS-driven cancers via PLK1 inhibition; competitors in the first-line space are not targeting the pan-RAS-mutated cohort.
- Regulatory Pathway: Seeking Accelerated Approval based on Overall Response Rate (ORR) and durability; targeting Full Approval based on Progression-Free Survival (PFS).
Macro / Industry Outlook:
- Regulatory: Secured Fast-Track Designation (announced Friday prior to conference) and Orphan Drug Designation for CMML and SCLC; successful End-of-Phase 2 meeting with FDA to define Phase 3 protocol.
- Economic/Operational: Planning a staged initiation of the Phase 3 trial to manage capital efficiency while accelerating timelines.
Strategic Initiatives:
- Phase 3 Trial (CARDF004 Extension): Design finalized after FDA interaction; will be adequately powered for Full Approval via PFS with an opportunity for Accelerated Approval via ORR; enrolling prospectively with PAN-RAS mutation criteria.
- Trial Logistics: Engaged Contract Research Organization (CRO); aiming to launch Phase 3 in Q1 2027.
- Upcoming Milestones: Presentation of updated CMML data at ASH in December; seeking feedback from European regulators.
Risks and Headwinds to Outlook:
- Trial Execution: Phase 3 is dependent on successful execution and patient enrollment; previous Phase 2 was not powered for PFS (current data is maturing/observational).
- Funding Dependency: While cash lasts until Q3 2027, future operations depend on raising capital or securing partnerships to sustain the multi-year development timeline post-runway.
- Regulatory Uncertainty: Accelerated approval is contingent on compelling ORR data; Full Approval requires mature PFS data which is still maturing in the ongoing Phase 2.
- Mechanistic Assumptions: The efficacy of Onvancitib is heavily tied to synergy with Irinotecan (Folfiri); outcomes with FOLFOX-Bev were less compelling, limiting the regimen choice.
Management Tone on the Future:
- Confidence: High confidence in the "compelling efficacy trends" (70% ORR vs. 42% control) and durability (patients on treatment >21 months) observed in Phase 2.
- Optimism: Described the data as providing "significant opportunity" to change practice in an area with "high and significant unmet need."
- Action-Oriented: Emphasizes active work with the FDA and CROs to minimize delay, stating the company is "working earnestly" toward the Phase 3 launch.
- Hedges: Explicitly acknowledges the Phase 2 study was small and not powered for PFS; notes that while PFS benefits are promising, they are not yet definitive in the current dataset.
Miscellaneous:
- Safety: Drug demonstrates a favorable tolerability profile with no significant additive toxicities when combined with Folfiri-Bev or FOLFOX-Bev, supporting long-term first-line administration.
- Surgical Outcomes: Several patients in the 30mg arm achieved tumor reduction sufficient to undergo curative surgery.
- Company
- CARDIFF ONCOLOGY INC
- Keywords
- CARDIFF ONCOLOGY INC